The benefits of targeting calcitonin gene-related peptide (CGRP) could go beyond migraine prevention, and three new studies report success with a new small-molecule CGRP receptor antagonist in acute migraine and with a monoclonal antibody in cluster headache.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Edvinsson, L., Haanes, K. A., Warfvinge, K. & Krause, D. N. CGRP as the target of new migraine therapies — successful translation from bench to clinic. Nat. Rev. Neurol. 14, 338–350 (2018).
Olesen, J. et al. BIBN 4096 BS Clinical Proof of Concept Study Group. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl. J. Med. 350, 1104–1110 (2004).
Lipton, R. B. et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N. Engl. J. Med. 381, 142–149 (2019).
Croop, R. et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet https://doi.org/10.1016/S0140-6736(19)31606-X (2019).
Goadsby, P. J. et al. Trial of galcanezumab in prevention of episodic cluster headache. N. Engl. J. Med. 381, 132–141 (2019).
Hargreaves, R. & Olesen, J. Calcitonin gene-related peptide modulators – the history and renaissance of a new migraine drug class. Headache 59, 951–970 (2019).
Ruff, D. D. et al. Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure. Cephalalgia 39, 931–944 (2019).
Ashina, M. et al. Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia 238, 1611–1621 (2018).
Vollesen, A. L. H. et al. Effect of infusion of calcitonin gene-related peptide on cluster headache attacks: a randomized clinical trial. JAMA Neurol. 75, 1187–1197 (2018).
Ashina, M., Hansen, J. M., Oladódottir á Dunga, B. & Olesen, J. Human models of migraine — short-term pain for long-term gain. Nat. Rev. Neurol. 13, 713–724 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.O. declares no competing interests. M.A. is a consultant or scientific advisor for Alder, Allergan, Amgen, Eli Lilly, Novartis and Teva, is a principal investigator for Alder, Amgen, ElectroCore, Novartis and Teva, and reports grant support from Novartis but has no ownership interest and does not hold stock in any pharmaceutical company. M.A. also serves as associate editor of Cephalalgia and Headache and as co-editor of the Journal of Headache and Pain.
Rights and permissions
About this article
Cite this article
Olesen, J., Ashina, M. Calcitonin gene-related peptide — beyond migraine prophylaxis. Nat Rev Neurol 15, 562–564 (2019). https://doi.org/10.1038/s41582-019-0258-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-019-0258-1
